Epstein–Barr virus latent membrane protein–1 expression in Hodgkin lymphoma

Ferdousy Begum, Prabir Kumar Saha, Tasmina Enam and Mohammed Kamal

Abstract

Expression of latent membrane protein-1 of Epstein-Barr virus is documented in Hodgkin lymphoma indicating its relationship in disease process. A total of 50 cases of Hodgkin lymphoma were analyzed for latent membrane protein-1 expression by immunohistochemistry. The mean age was 28.7 years with male predominance. Mixed cellularity classical Hodgkin lymphoma was the commonest subtype (50% cases). Out of 50 cases, 48% cases were found positive for latent membrane protein. Of the five histologic subtypes, all cases of lymphocyte depleted classical Hodgkin lymphoma showed positivity which was followed by 60% positivity of mixed cellularity classical Hodgkin lymphoma. Association of latent membrane protein-1 expression in relation to different age group, site of involvement and subtypes of Hodgkin lymphoma were found statistically insignificant while latent membrane protein-1 expression was significantly higher in male than female.

Introduction

Hodgkin lymphoma is an unusual malignancy because only a small number of cells constitute the tumor mass. This small fraction of cells are admixed with abundant heterogeneous population of non-neoplastic inflammatory and accessory cells. As a result, the study on these cells is challenging. Regarding pathogenesis of the Hodgkin lymphoma, it is found that Epstein-Barr virus is associated with some fractions which are causal. The detection of Epstein-Barr virus in Hodgkin lymphoma, its pattern of positivity in different subtypes of Hodgkin lymphoma along with their correlation with demographics of 50 cases of Hodgkin lymphoma in terms of age and gender.

Materials and Methods

A total of 50 cases of Hodgkin lymphoma were obtained from the Pathology Department from January 2013 to December 2016. The clinical parameters like age and gender were recorded from the patient’s requisition form. All hematoxillin and eosin stained slides were reexamined and classified according to WHO Classification 2008 into five subtypes viz. nodular sclerosis classical Hodgkin lymphoma, mixed cellularity classical Hodgkin lymphoma, lymphocyte rich classical Hodgkin lymphoma, lymphocyte depleted classical Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin lymphoma.
All cases were examined for latent membrane protein-1 detection by immunohistochemical stain. Thin sections (4.0 µm) were taken on poly-L-lysine coated slides from the selected paraffin blocks. The slides were air-dried and incubated for 16 hours at 37°C in an incubator. Dewaxing of slides was done by subsequent two changes in xylene for 5 min duration each. Then the slides were treated with Dako target retrieval solution (Code No. S1700). Retrieval solution was taken in coplin jar and preheated in the water bath at 65°C. The slides were kept in this solution and heated in the water bath at 95-99°C for 30-40 min. After 20 min, each slide was washed with deionized water for 5 min. Peroxidase–blocking solution DakoReal™ (Code No S2023) applied for 10 min followed by wash in Tris buffer saline for 5 min. Monoclonal mouse anti-Epstein-Barr virus, LMP clones CS, 1-4 (Code No M0897) was used as the primary antibody with a dilution of 1:200 and incubated for 30 min. This was followed by Tris buffer saline wash 5 min twice. The incubation in Envision™ Detection System, HRP, rabbit/mouse, (code K5007) was done for 30 min followed by wash in Tris buffer saline for 5 min twice. Application of 3,3-diaminobenzidine substrate (DAB) was used as chromogen and kept for 10 min. This step was followed by deionized water wash. Counter-staining of nucleus was performed by Mayer’s Hematoxillin for 2 min. Dehydration was done by increasing strength of isopropyl alcohol (70, 80, 90 and 100%), each step for 10 min. Clearing was done by subsequent two changes in xylene for 5 min duration each. The slide was mounted with DPX. Immunostaining procedure was performed according to Dako, Denmark product Envision™ Detection System, HRP, rabbit/mouse, (code K5007). Each case was run with control slide (diagnosed positive case of Hodgkin lymphoma). Cytoplasmic and membrane staining of the latent membrane protein-1 were interpreted as positive. Hematoxillin was used as counter stain (Figure 1).

**Statistical analysis**

Statistical analysis was done using SPSS version 20. Chi-square test of independence was used to find out the association of latent membrane protein-1 expression between/among different age group, gender and subtypes of Hodgkin lymphoma along with latent membrane protein-1 positivity.

**Results**

Among the 50 studied cases of Hodgkin lymphoma, 48% cases were positive for Epstein-Barr virus latent membrane protein-1 by immunohistochemistry (Table I).

The age of studied cases ranged from 4 to 75 years with the mean age of 28.7 years (SD ± 16.95). Male cases outnumbered the female (76/24%).

Among the subtypes of Hodgkin lymphoma, latent membrane protein-1 was found 100% positivity in lymphocyte depleted classical Hodgkin lymphoma followed by 60% in mixed cellularity classical Hodgkin lymphoma, 41.7% in classical Hodgkin lymphoma, unclassifiable, 30% in nodular sclerosis classical Hodgkin lymphoma and 0% each for lymphocyte rich classical Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin lymphoma (Table I).
The association of latent membrane protein-1 expression in relation to different age group and subtypes of Hodgkin lymphoma was found statistically insignificant. However, the mentioned association was found statistically significant in respect to gender (Table I).

**Discussion**

This study shows 48% positivity in Hodgkin lymphoma. Only the positivity of latent membrane protein-1 in male patients (55.3%) were significantly higher than the females, however the association of latent membrane protein-1 expression in relation to different age group and subtypes of Hodgkin lymphoma was found statistically insignificant. The most common subtype was mixed cellularity classical Hodgkin lymphoma with 60% latent membrane protein-1 positivity, however lymphocyte depleted classical Hodgkin lymphoma showed 100% positivity (Table I). In addition, each case of nodular lymphocyte predominance Hodgkin lymphoma and lymphocyte rich classical lymphoma showed negativity to the latent membrane protein-1.

Glasser et al. (1997) reported 50% positivity of latent membrane protein-1 in Hodgkin lymphoma with significant male predominance in their international data of epidemiologic characteristics of Epstein-Barr virus-associated Hodgkin disease cases. Male predominance has also been reported by Ambinder et al. (1993) in Honduras and in the United States and Gully et al. (1994) in Hispanic American ethnicity.

Percentage of latent membrane protein-1 positivity in Reed Sternberg cells of Hodgkin lymphoma has wide range of variation noticed in studied cases of different countries. Chang et al. (1993) found 83% positivity in Peru whereas cases from USA, Italy and Greece studied by Herling et al. (2003) found 21%.

In Pakistan, Hashmi et al. (2007) and Fatima et al. (2011) found 68.1% and 60% respectively. Latent membrane protein-1 positivity in India described by Radha et al. (1997) in Chennai as 31%, Karnik et al. (2003) as 82% and Rajalakshmi et al. (2006) as 55%.

Latent membrane positivity in different countries is reflected by socioeconomic condition, geographical location and ethnicity of people. This study showed 48% positivity which is more or less close to the findings of Pakistan and some area of India.

Mixed cellularity classical Hodgkin lymphoma subtype has been described as most predominant form by others which is similar to the present study whereas a large study performed by Campos et al. found nodular sclerosis classical Hodgkin lymphoma to be most common subtype.

Hodgkin lymphoma is presented with bimodal age incidence. In developing countries, the first age incidence peak occurs in childhood and the second peak occurs in elderly patients. However in developed countries the first peak delayed until young adulthood. Dinand et al. found statistically significant association between Epstein-Barr virus-latent membrane protein-1 detection in younger age group of Indian children. This study also described statistically significant association between Epstein-Barr virus-latent membrane protein-1 detection and middle-low socioeconomic status as compared with the higher socioeconomic status.

There is no statistically significant differences found between <15 years age group, 15-50 years age group and >50 years age group in our series.

The mean age of Hodgkin lymphoma cases of the present study is similar to the study performed by others but lower than Cickusic et al. (2007).

However, a retrospective analysis of diagnosed hematological malignancies in Bangladesh over
5,000 cases has reported median age of Hodgkin lymphoma to be 36 years. The present study showed that male patients are more affected by the Hodgkin lymphoma than the females. This finding is similar to the earlier studies. Histological features like background lymphocyte population, presence of fibrosis, relative percentage of Reed-Sternberg cells and immunophenotype determine the histologic subtypes of Hodgkin lymphoma. Nodular sclerosis Hodgkin lymphoma is the most commonly encountered type in USA. People of higher socioeconomic status have predominant nodular sclerosis Hodgkin lymphoma subtype and lower socioeconomic condition have mixed cellularity Hodgkin lymphoma subtype described in a study performed. Like the variation of these two histologic subtypes of Hodgkin lymphoma percentages of latent membrane protein-1 expression also varies. Regarding the latent membrane protein-1 expression in mixed cellularity Hodgkin lymphoma subtypes Ambinder et al. (1993) found 100% positive cases of latent membrane protein-1 in Honduras and 85.7% cases in USA, Hashmi et al. (2007) found 73.9% positive cases in Pakistan, Armstrong et al. (1993) 100% positive cases in Saudi Arabia, Sughayer et al. (2014) found 80.7% positive cases in Jordan. The present study showed 60% positive cases which is lower in comparison to others data. One explanation could be due to inclusion of 24% cases of unclassifiable classical Hodgkin lymphoma in our series.

In this study, Epstein-Barr virus latent membrane protein-1 positive staining was seen in 100% cases of lymphocyte depleted classical Hodgkin lymphoma subtype. A study carried out in Iran found 100% positive cases of latent membrane protein-1 in lymphocyte depleted classical Hodgkin lymphoma subtype while in Pakistan Hashmi et al. (2007) found 66.6% positive cases in this subtype.

Regarding pathogenesis of Hodgkin lymphoma, several molecular studies on Reed-Sternberg cells and its variants have shown V(D)J recombination and somatic hypermutation. This established that origin of the malignant cells is from germinal center or postgerminal center B cells. Despite presence of genetic signature of B cells, most B cell specific genes including Ig genes are not expressed in Reed-Sternberg cells. This may be due to epigenetic changes of unknown etiology. The concept of causal association of Hodgkin lymphoma and infectious agent was proposed by MacMahon in 1966. Initially raised antibody titers to Epstein-Barr virus antigen was found in patients with Hodgkin lymphoma. Epstein-Barr virus could play role in the pathogenesis of Hodgkin lymphoma either by direct infection or indirectly. Moreover, direct or acquired depression of immunoregulation might be responsible for reactivation of Epstein-Barr virus or causation of malignancy. Epithelial cells of oropharynx and B lymphocytes are infected by Epstein-Barr virus. The virus enters into the B lymphocytes with the help of CD21 which is present on all B lymphocytes. Within the B cell, genome of Epstein-Barr virus transform to episomal form within the nucleus. This is supported by study performed by Deacon et al. In latently infected cells the viral genes cause desregulation of normal proliferation and survival signals. A signaling molecule that is usually stimulated by CD40 receptor in B cells is triggered by latent membrane protein-1. CD40 receptor plays a key role in helper T cell signals which control B cell responses. Latent membrane protein-1 like CD40 receptor activates NF-kB and JAT/STAT signaling pathways that leads to the sustained survival and proliferation of B cells. NF-kB transcription factor activation is a common event that occur by several mechanism. This may be activated by Epstein-Barr virus infection or other mechanism. During natural infection of B cells by Epstein-Barr virus six nuclear proteins (called either EBNA1-6, or EBNA1, 2, 3a, 3b, 3c and LP), three membrane proteins (LMP1 and LMP2A and 2B protein) and two small non-polyadenylated RNA transcripts (EBERs) are expressed. Hodgkin and Reed Sternberg cells express EBNA1, LMP1 and LMP2A and 2B protein and EBERRNAs, the so called latency II pattern of transcription. Among the latent membrane proteins, latent membrane protein-1 involves in the activation of NF-kB transcription factor. So, its detection may be related to causal. The potential importance of LMP1 in the pathogenesis of Hodgkin lymphoma is being reflected by present study which showed 48% positivity of LMP1 in Hodgkin lymphoma cases by immunohistochemistry.

A population based study on Epstein-Barr virus status of Hodgkin lymphoma showed that Epstein-Barr virus negative cases have better disease specific survival rate. Moreover, it has already been established that vaccine and antiviral drugs can modulate the clinical course of infectious mononucleosis virus which is detected in some Hodgkin lymphoma. Their impact on Hodgkin lymphoma is not known. T-cell function may have important role in Hodgkin lymphoma because higher CD4 counts are associated with an increased incidence of Epstein-Barr virus positive Hodgkin lymphoma in HIV patients. Treatment related to adoptive immunotherapy with T cells targeting Epstein-Barr virus antigens has been investigated. Recent advances in targeted therapy have shown more effective therapeutic impact on Hodgkin lymphoma. So, the detection of Epstein-Barr virus association in biopsy samples either by identification of latent membrane protein-1 by immunohistochemistry or Epstein-Barr virus encoded RNA by in situ hybridization will be utilized for targeted therapy in future.
Conclusion

Forty eight percentage cases of the present study series of Hodgkin lymphoma expressed latent membrane protein-1 positivity. Among other parameters male patients showed significant positivity (55.3% cases) of latent membrane protein-1 than the female. Though the mixed cellularity classical Hodgkin lymphoma was found to the most common subtype (50% cases), their association with latent membrane protein-1 showed 60% positivity while 100% cases of lymphocyte depleted classical Hodgkin lymphoma showed positivity for latent membrane protein-1.

References

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon, International Agency for Research on Cancer, 2008; pp 322-34.

2. Flavell KJ, Murray PG, Hodgkins disease and Epstein-Barr virus. J Clin Pathol Mol Pathol. 2000; 53: 262-69.

3. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS. Epstein-Barr virus and Hodgkin’s disease: Transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993; 177: 339-49.

4. Gulley ML, Glaser SL, Craig FE, Borowitz M, Mann RB, Shema SJ, Ambinder RF. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002; 117: 259-67.

5. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsog G, Pallesen G. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin’s disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993; 82: 2937-42.

6. Glaser SL, LinRj, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, Pallesen G, Gulley ML, Khan G, Grady JO, Hummel M, Preciado MV, Knecht H, Chan JKC, Clavienz A. Epstein-Barr virus-associated Hodgkin’s disease: Epidemiologic characteristics in international data. Int J Cancer. 1997; 70: 375-82.

7. Ambinder RF, Browning PJ, Lorenzana I, Leventhal BG, Cosenza H, Mann RB. Epstein-Barr virus and childhood Hodgkin’s disease in Honduras and the United States. Blood 1993; 81: 462-67.

8. Gulley ML, Eagan PA, Martinez LQ, Picado AL, Smir BN, Childs C, Dunn CD, Craig FE, Williams Jr JW, Banks PM. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin’s disease: Association with mixed cellularity subtype and Hispanic American ethnicity. Blood 1994; 83: 1595-602.

9. Chang KL, Albujar PF, Chan YY, Johnson RM, Weiss LM. High prevalence of Epstein-Barr virus in the Reed Sternberg cells of Hodgkin’s disease occurring in Peru. Blood 1993; 81: 496-501.

10. Herling M, Rassidakis GZ, Medeiros LJ, Vassilakopos TP, Klichi KO, Nasal M, Viviani S, Bonfante V, Giardini R, Chiles M, Kittas C, Giannii AM, Pizzolo GBG, Pangaless GA, Canabillas F, Sarris AH. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma: Associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003; 9: 2114-20.

11. Hashmi AA, Hussain ZF, Hashmi KA, Zafar MI, Edni MM, Faridi N, Khan M. Latent membrane protein-1 expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters. World J Surg Oncol. 2007; 15: 89-93.

12. Fatima S, Ahmed R, Ahmed A, Hodgkin lymphoma in Pakistan: An analysis of subtypes and their correlation with Epstein-Barr virus. Asia Pac J Cancer Prev. 2011; 12: 1385-88.

13. Radha K, Shanthi P, Madhavan M, Senthamarai A. Study of association of Epstein-Barr virus with Hodgkin’s disease. Indian J Pathol Microbiol. 1997; 40: 351-54.

14. Karnik S, Srinivasan B, Nair S. Hodgkin’s lymphoma: Immunohistochemical features and its association with EBV LMP-1: Experience from a South Indian hospital. Pathology 2003; 35: 207-11.

15. Rajalakshmi T, Payal K, Makhija P, Karuna V. Epstein-Barr virus in Hodgkin’s lymphoma: Incidence and prognostic implications. Indian J Med Paed Oncol. 2006; 27: 23-26.

16. Irshaid F, Tarawneh K, Alshdefata A, Dilmi F, Janar A, Al-Hadithi R, Al-Khatib A. Loss of P16 protein expression and its association with Epstein-Barr Virus LMP-1 expression in Hodgkin’s lymphoma. Iran J Cancer Prev. 2013; 2: 78-84.

17. Čičkušić E, Mujanović JM, Iljazović Z, Škaljić I. Association of Hodgkin’s lymphoma with Epstein-Barr virus infection. Bosnian J Basic Med Sci. 2007; 7: 58-65.

18. Islam F, Ahmed S, Yasmeen BHN, Mannan MA, Parvin R, Parvin R. Clinicopathological profile of Hodgkin’s lymphoma in children. Northern Int Med Coll J. 2013; 4: 273-76.

19. Campos AHJFM, Moreira A, Ribeiro KB, Paes RP, Zerbini MC, Aldred V, Souza CAD, Neto CS, Soares FA, Vassallo J. Frequency of EBV associated classical Hodgkin lymphoma decreases over a 54-year period in a Brazilian population. Sci Reports. 2018; 8: 1849-56.

20. Armstrong AA, Alexander FE, Paes RP, Morad NA, Gallagher A, Krajeswki AS, Jones DB, Angus B,
21. Dinand V, Dawarb R, Aryac LS, Unnib R, Mohanty B, Singh R. Hodgkin’s lymphoma in Indian children: Prevalence and significance of Epstein-Barr virus detection in Hodgkin’s and Reed-Sternberg cells. Eur J Cancer. 2007; 43: 161-68.

22. Ziaullah S, Ahmad S, Khan MM, Alam S, Nasir S, Sharif N. Epstein-Barr virus LMP-1 positivity in Hodgkin’s lymphoma subtypes, in Khyber Pakhtunkhwa Province of Pakistan. Gomal J Med Sci. 2017; 15: 3-7.

23. Hossain MS, Iqbal M, Khan MA, Rabbani MG, Khatun H, Munira S, Miah MMZ, Kabir AL, Islam N, Dipta TF, Rahman F, Mottalib A, Afrose S, Ara T, Biswas AR, Rahman M, Abedin AKMM, Rahman M, Yunus ABM, Neissen LW, Sultana TA. Diagnosed hematological malignancies in Bangladesh: A retrospective analysis of over 5000 cases from 10 specialized hospitals. BMC Cancer. 2014; 14: 438-44.

24. Sughayer MA, Haddad HA, Al-Yousef RM, El-Khateeb M, Abu-Rass H. Epstein-Barr virus and Hodgkin lymphoma in Jordan. Hematol Oncol Stem Cell Ther. 2014; 7: 85-89.

25. Kumar V, Abbas AK, Aster JC. Diseases of white blood cells, lymph nodes, spleen, and thymus. In: Robbins & Cotran Pathologic Basis of Disease. Kumar V, Abbas AK, Aster JC (eds). 9th ed. Philadelphia, Elsevier Saunders, 2015, pp 606-07.

26. MacMahon B. Epidemiology of Hodgkins disease. Cancer Res. 1996; 26: 1189-200.

27. Levine PH, Ablashi DV, Berard CW, Carbone PP, Waggner DE, Malan L. Elevated antibody titers to Epstein-Barr virus in Hodgkin’s disease. Cancer 1971; 27: 416-21.

28. Jarrett RF. Epstein-Barr virus and Hodgkin’s disease. Epstein-Barr virus Rep. 1998; 5: 77-85.

29. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Fields Virology. Knipe DM, Howley PM (eds). 4th ed. Philadelphia, Lippincott Williams and Wilkins, 2001, pp 2511-75.

30. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields Virology. Knipe DM, Howley PM (eds). 4th ed. Philadelphia, Lippincott Williams and Wilkins, 2001, pp 2575-627.

31. Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study. Blood 2005; 106: 2444-51.

32. Ambinder RF, Epstein-Barr virus and Hodgkin’s lymphoma. Am Soc Hematol. 2007: 204-09.